BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring
Yahoo Finance ·
BioNTech ( BNTX +0.25% ) rose to prominence several years ago thanks to its role in the coronavirus market. The company developed Comirnaty, one of the best-selling COVID-19 vaccines, with Pfizer ( PFE +0.83% ) . However, vaccination rates have dropped significantly due to a combination of factors, including stricter market regulations. As a result, BioNTech's coronavirus business hasn't performed well recently. The good news is that the company's future no longer depends on its work in this industry. There is another much larger area BioNTech is targeting. Here's what investors need to know. The weight-loss market is grabbing headlines for its rapid growth. But the largest area in the industry by annual sales remains oncology . There are several reasons for that. Let's consider four of them. First, cancer is one of the world's leading causes of death. According to some estimates, in the U.S., one person in three will be diagnosed with cancer at some point in their lives. So, it is a fairly common disease with a significant annual death toll. Second, the oncology market is massive. There are dozens of types of cancer, and some corners of the industry remain underserved, which can attract even more drugmakers. Third, because cancer is a life-threatening condition, regulators often grant cancer medicines in development special designations that can help speed up approval, a factor that incentivizes drugmakers to develop more of them. Lastly, cancer medicines often command high prices and can sometimes be administered over years. The cancer therapeutics space will continue to expand, and, according to some estimates, it will be worth $516.2 billion by 2035, with a compound annual growth rate of 9.3% over that period. That's the market where BioNTech is looking to carve out a meaningful niche. Can the company pull it off?
DYAX Investor Sentiment
Bullish (Long) 40% · Bearish (Short) 60%
444 participants
Related News
- Intel forecasts Q3 2026 EPS of $0.38 on $15.8B-$16.8B revenue while planning 2026 CapEx above $20B
- Robert Half outlines Q3 revenue of $1.31B-$1.41B as Protiviti targets $45M annualized savings
- Old Republic expects ECM to run at a 90%-95% combined ratio, as it flags a bargain purchase gain next quarter
- Knowles forecasts 10%-12% 2026 revenue growth as defense demand drives multiyear orders into 2027
- Freeport outlines Grasberg ramp to 80% by mid-2027 as Bagdad capex nears $4.5B
- Overseas demand rises for U.S. crude as war-induced volatility sends buyers scrambling
